Maha Hussain
Medical Oncology · Ann Arbor, MINPI 1245316199
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $81,426 of the $114,473 with a category attached, or 71.1%. It is spread thinly across 22 manufacturers, the largest accounting for just 19.5%. Reporting peaked in 2019 at $39,062 and has fallen 56.4% since, to $17,013 in 2025. Among medical oncology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 92 payments — averaging $1244.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$22K
- F. Hoffmann-la Roche AG$14K
- Bayer$12K
- Merck$10K
- Pfizer$9K
- AbbVie$8K
- plus $39K from 16 others
Across 102 payments — averaging $29,087 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$2.1M
- Medivation LLC.$288K
- Pfizer$225K
- Bayer$165K
- Genentech, Inc.$141K
- Epizyme, Inc.$35K
- plus $32K from 4 others
What the payments were for
- Consulting fees$81,42671%
- Speaking & faculty fees$15,70014%
- Travel & lodging$14,22712%
- Food & beverage$3,1203%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 8 | $22,291 |
| F. Hoffmann-la Roche AG | 5 | $13,777 |
| Bayer | 19 | $12,430 |
| Merck | 4 | $9,796 |
| Pfizer | 11 | $8,729 |
| AbbVie | 12 | $8,325 |
| Astellas Pharma US Inc | 2 | $7,393 |
| E.r. Squibb & Sons, L.L.C. | 3 | $6,520 |
| AstraZeneca | 7 | $4,775 |
| Janssen Scientific Affairs, LLC | 3 | $3,243 |
| Novartis | 1 | $3,200 |
| GSK | 2 | $3,200 |
| Advanced Accelerator Applications | 1 | $3,000 |
| Daiichi Sankyo Inc. | 3 | $2,020 |
| Janssen Global Services, LLC | 1 | $1,925 |
| Sanofi | 2 | $1,701 |
| Johnson & Johnson | 3 | $1,667 |
| Progenics Pharmaceuticals, Inc. | 1 | $198 |
| Blue Earth Diagnostics | 1 | $155 |
| Sumitomo Pharma America, Inc. | 1 | $84 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Roche Products Limited | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$114,473 in reported general payments places this provider in the 90th percentile of 170 medical oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NubeqaDarolutamide | 75 | $940,020 |
| XtandiEnzalutamide | 38 | $577,822 |
| Abiraterone Acetate | 57 | $108,689 |
| OrgovyxRelugolix | 13 | $32,948 |
| Bicalutamide | 18 | $425 |
| Prednisone | 39 | $207 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerNubeqa | $12,430 | $940,02075 claims |
| Astellas Pharma US IncXtandi | $7,393 | $577,82238 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $3,243 | $108,68957 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $84 | $32,94813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 170 medical oncology providers in Michigan.
Other medical oncology in Ann Arbor
- Harry ErbaAnn Arbor$1.1M
- Frank WeinbergAnn Arbor$195K
- Francis WordenAnn Arbor$142K
- Moshe TalpazAnn Arbor$83K
- Vaibhav SahaiAnn Arbor$80K
- Howard TerebeloAnn Arbor$47K
- Angel QinAnn Arbor$41K
- Erin CobainAnn Arbor$38K
- Phillip PalmbosAnn Arbor$37K
- Rashmi ChughAnn Arbor$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.